摘要
目的:应用循证医学系统评价二仙汤治疗绝经后骨质疏松症(Postmenopausal Osteoporosis,PMOP)的临床疗效及安全性。方法:全面检索PubMed、Cochrane Library、Springer Link英文数据库,中国知网、万方、百链云图书馆中文数据库中公开发表的二仙汤或其加减方治疗PMOP的临床随机对照试验,检索时间为自建库至2019年12月。用RevMan 5.3软件对符合纳入标准的研究结果进行Meta分析。结果:共检索相关文献164篇,最后纳入研究的共12篇,总样本量1060例。Meta分析得出采用二仙汤联合其他治疗措施在提高临床有效率[OR=3.56,95%CI(2.37,5.35),Р<0.00001],改善腰椎骨密度(Bone Mineral Density,BMD)[SMD=0.88,95%CI(0.70,1.06),Р<0.00001;SMD=0.54,95%CI(0.26,0.82),Р=0.0002]、股骨颈骨密度[SMD=0.62,95%CI(0.44,0.79),Р<0.00001]、股骨粗隆骨密度[SMD=0.18,95%CI(0.79,1.57),Р<0.00001;SMD=0.63,95%CI(0.35,0.92),Р<0.0001]、Ward’s三角骨密度[SMD=0.71,95%CI(0.34,1.07)、Р=0.0002;SMD=1.06,95%CI(0.76,1.35),Р<0.00001]方面显著优于单用其他治疗措施。结论:二仙汤在改善PMOP患者腰椎及髋部骨密度、提高临床有效率方面疗效确切,并且可以提高PMOP患者雌二醇(Estradiol,E2)水平,改善PMOP患者碱性磷酸酶(Alkaline Phosphatase,ALP)、血清钙(Calcium,Ca)、血清磷(Phosphorus,P)、骨钙素(Bone Gla Protein,BGP)、降钙素(Calcitonin,CT)水平,在安全性方面缺少文献支持。
Objective:To systematically evaluate the clinical efficacy and safety of the Erxian decoction(二仙汤)on postmenopausal osteoporosis by evidence-based medicine.Methods:The literature on clinical randomized controlled trials of treating PMOP with the Erxian decoction from database construction to December 2019 was retrieved in English databases PubMed,Cochrane Library,Springer Link,Chinese databases CNKI,Wanfang database and Bailianyun libraries.A meta-analysis on the results of the studies that met the included criteria was performed by RevMan 5.3 software.Results:A total of 164 related studies were retrieved,and 12 articles were included finally in the study,with a total sample size of 1060 cases.The meta-analysis shows that the Erxian decoction plus other treatment measures was significantly better than other treatment measures alone in improving clinical efficacy[OR=3.56,95%CI(2.37,5.35),P<0.00001],and ameliorating lumbar BMD[SMD=0.88,95%CI(0.70,1.06),P<0.00001;SMD=0.54,95%CI(0.26,0.82),P=0.0002],femoral neck BMD[SMD=0.62,95%CI(0.44,0.79),P<0.00001],femoral trochanter BMD[SMD=0.18,95%CI(0.79,1.57),P<0.00001;SMD=0.63,95%CI(0.35,0.92),P<0.0001]and Ward’s triangle BMD[SMD=0.71,95%CI(0.34,1.07),P=0.0002;SMD=1.06,95%CI(0.76,1.35),P<0.00001].Conclusion:The Erxian decoction is effective in improving BMD of lumbar spine and hip of PMOP patients,and clinical efficacy.It can also increase E2 level of PMOP patients and improve ALP,Ca,P,BGP and CT in PMOP patients.However,there is a lack of literature support on the safety.
出处
《中医临床研究》
2021年第29期10-15,共6页
Clinical Journal Of Chinese Medicine
关键词
二仙汤
绝经后骨质疏松症
系统评价
META分析
The Erxian decoction
Postmenopausal osteoporosis
Systematic review
Meta analysis
